The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical circulating tumor DNA (ctDNA) shedding duration and prognostic implications of modeling 3669 participants from American Cancer Society Cancer Prevention Study-3 (CPS-3) and Circulating Cell-free Genome Atlas substudy 3 (CCGA3).
 
Alpa Patel
Research Funding - GRAIL (Inst)
 
Christina A. Clarke
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
 
Emily L Deubler
No Relationships to Disclose
 
Eric T. Fung
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
Patents, Royalties, Other Intellectual Property - GRAIL
 
Roger Jiang
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
 
Cari Lichtman
No Relationships to Disclose
 
Lauren R. Teras
No Relationships to Disclose
 
Oliver Venn
Employment - Gilead Sciences (I); GRAIL
Stock and Other Ownership Interests - Applied Molecular Transport (I); Gilead Sciences (I); GRAIL; Illumina; Moderna Therapeutics
Research Funding - GRAIL
Patents, Royalties, Other Intellectual Property - Arising from work at GRAIL Inc.
Travel, Accommodations, Expenses - GRAIL
 
Nan Zhang
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
Patents, Royalties, Other Intellectual Property - Pending patent to the microsimulation methodology to evaluate multi-cancer early detection test
Travel, Accommodations, Expenses - GRAIL
 
Earl A. Hubbell
Employment - GRAIL
Stock and Other Ownership Interests - Illumina
Research Funding - GRAIL
Patents, Royalties, Other Intellectual Property - GRAIL: filed patent applications
Travel, Accommodations, Expenses - GRAIL
 
Charles Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Apogen Biotechnologies; Bicycle Therapeutics; Epic Sciences; GRAIL
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; Amgen; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GRAIL; Illumina; Medicxi; Medicxi; Metabomed; MSD; Novartis; Pfizer; Roche; Roche; Sarah Cannon Research Institute
Research Funding - Archer; AstraZeneca; BMS; Boehringer Ingelheim; Ono Pharmaceutical; Personalis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Immune checkpoint intervention in cancer (PCT/EP2016/071471),; Method for determining whether an HLA allele is lost in a tumour (PCT/GB2018/052004); Method for identifying responders to cancer treatment (PCT/GB2018/)051912); Method for treating cancer (PCT/EP2016/059401).; Method for treating cancer based on identification of clonal neo-antigens (PCT/EP2016/059401); Method of detecting tumour recurrence (PCT/GB2017/053289); Method of identifying insertion/deletion mutation targets (PCT/GB2018/051892); Method of predicting survival rates for cancer patients (PCT/GB2020/050221); Methods for lung cancer detection (PCT/US2017/028013)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst)